Breathtec Announces Name Change to Algernon Pharmaceuticals
15 February 2019 - 12:22AM
InvestorsHub NewsWire
-
New corporate identity
aligned with the Company's main strategy to be a global leader in
the treatment of liver disease (NASH), chronic kidney disease and
inflammatory bowel
disease.
-
The company's ticker
symbol will change to "AGN" on the Canadian Securities Exchange
effective before market opens on Tuesday, February 19,
2018.
-
The Company’s lead
compound for liver disease (NASH) reduced fibrosis in a
pre-clinical research study by
84.4%.
-
The company will
continue to advance its medical device FAIMS program through its
agreement with the University of
Florida.
VANCOUVER, British Columbia
-- Feb. 14, 2019 -- InvestorsHub NewsWire -- Breathtec Biomedical
Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)
(OTCQB: BTHCF) (the
“Company” or
“Breathtec”) is pleased to announce
that as a result of the strength of the data from its Nash
Pharmaceuticals pre-clinical research program, it will be changing
its name to Algernon Pharmaceuticals Inc.
The change will take place
before market opens on February 19, 2019 and the Company's ticker
symbol will change from "BTH to "AGN" on the Canadian Securities
Exchange. Changes to the symbol for the Frankfurt and OTCQB
exchanges are in progress and the Company will provide an update on
the new symbols shortly. The Company’s new website will also be
activated on February 19, 2019 and can be found at www.algernonpharmaceuticals.com.
The name Algernon was inspired
in part, by the Hugo Award winning, 1959 science fiction short
story “Flowers for Algernon”, which was a story about change and
transition.
“We are very pleased to be
moving forward with our corporate rebranding,” said Christopher J.
Moreau, CEO of Algernon Pharmaceuticals Inc. “Based on the success
of our pre-clinical drug development program, we believe that this
change will help to communicate to the market, our excitement and
confidence in our newly established drug research
program.”
About Algernon
Pharmaceuticals Inc.
Algernon Pharmaceuticals is a
clinical stage pharmaceutical development company focused on
advancing its lead compounds for of non–alcoholic steatohepatitis
(NASH), chronic kidney disease (CKD) and inflammatory bowel disease
(IBD).
CONTACT
INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com
The CSE does
not accept responsibility for the adequacy or accuracy of this
release.
Neither the
Canadian Securities Exchange nor its Market Regulator (as that term
is defined in the policies of the Canadian Securities Exchange)
accepts responsibility for the adequacy or accuracy of this
release. The Canadian Securities Exchange has not in any way passed
upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press
release.
CAUTIONARY DISCLAIMER
STATEMENT: No Securities Exchange has reviewed nor accepts
responsibility for the adequacy or accuracy of the content of this
news release. This news release contains forward-looking statements
relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not
historical facts. Forward-looking statements are often identified
by terms such as “will”, “may”, “should”, “anticipate”, “expects”
and similar expressions. All statements other than statements of
historical fact, included in this release are forward-looking
statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure to satisfy the conditions of the relevant
securities exchange(s) and other risks detailed from time to time
in the filings made by the Company with securities regulations. The
reader is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.